B. Patel

发表

Reporting guidelines for population pharmacokinetic analyses

C. Tornøe, N. Al-Huniti, K. Dykstra, 2015, Journal of Pharmacokinetics and Pharmacodynamics.

Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics

D. Chang, B. Patel, M. Chu, 2013, The Journal of Rheumatology.

Evaluation of vardenafil and sildenafil on cardiac repolarization.

Timothy H. Montague, G. Dabiri, V. Sethuraman, 2004, The American journal of cardiology.

Reporting guidelines for population pharmacokinetic analyses

C. Tornøe, N. Al-Huniti, K. Dykstra, 2015, Journal of Pharmacokinetics and Pharmacodynamics.

Randomized Controlled Trial of Early Outpatient COVID-19 Treatment with High-Titer Convalescent Plasma

A. Casadevall, B. Lau, D. Hanley, 2021, medRxiv.

IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial.

D. Leongamornlert, E. Papaemmanuil, A. Moorman, 2021, Blood advances.

Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis

A. Hagenbeek, B. Coiffier, M. Østergaard, 2014, Journal of clinical pharmacology.

Validation of MRI Measurement of Cardiac Output in the Dog: The Effects of Dobutamine and Minoxidil

P. Hockings, A. Busza, A. White, 2003, Toxicology mechanisms and methods.

Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects

J. Wagg, R. Mehta, Michelle L. Green, 2016, Journal of Pharmacokinetics and Pharmacodynamics.

Utility of concentration‐effect modeling and simulation in a thorough QT study of losmapimod

L. Tombs, N. Arya, B. Patel, 2015, Journal of clinical pharmacology.

Ric-8A gene deletion or phorbol ester suppresses tumorigenesis in a mouse model of GNAQQ209L-driven melanoma

G. Tall, B. Patel, 2016, Oncogenesis.

Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement.

J. Bartram, A. Fielding, B. Patel, 2020, Seminars in hematology.

Tafenoquine at therapeutic concentrations does not prolong fridericia-corrected QT interval in healthy subjects

M. McDonald, S. Duparc, B. Patel, 2014, Journal of clinical pharmacology.

Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumors

L. Ottesen, B. Patel, H. Kallender, 2015, Journal of clinical pharmacology.

Concentration-QT analysis of the randomized, placebo- and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects

J. Wagg, R. Mehta, B. Patel, 2016, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacokinetic and Pharmacodynamic Basis for Effective Argatroban Dosing in Pediatrics

J. Gobburu, G. Young, B. Patel, 2011, Journal of clinical pharmacology.

Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours

A. Tolcher, Sunil Sharma, K. Papadopoulos, 2016, Cancer Chemotherapy and Pharmacology.

Discovery of a Selective S1P1 Receptor Agonist Efficacious at Low Oral Dose and Devoid of Effects on Heart Rate.

S. Dowell, E. Demont, J. Witherington, 2011, ACS medicinal chemistry letters.

Reporting guidelines for population pharmacokinetic analyses

C. Tornøe, N. Al-Huniti, K. Dykstra, 2015, Journal of Pharmacokinetics and Pharmacodynamics.

Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection

A. Casadevall, B. Lau, L. Appel, 2021, medRxiv.

A definitive study of the effects of PDE‐5 inhibitors on cardiac repolarization in middle‐age males

G. Dabiri, V. Sethuraman, J. Morganroth, 2004 .

Metformin reduces SARS-CoV-2 in a Phase 3 Randomized Placebo Controlled Clinical Trial

David M. Liebovitz, Tejas Mehta, D. Boulware, 2023, medRxiv.